Literature DB >> 10640257

The UK migraine patient survey: quality of life and treatment.

A Dowson1, S Jagger.   

Abstract

This research confirms that a majority of migraine sufferers in the UK acknowledge an incidence, frequency and symptomatology that have a significant effect on quality of life (both activity-based and on personal relationships); despite this, a significant proportion self-medicate with unsuitable and ineffective agents owing to the low level of efficacy and general lack of satisfaction with recommended and prescribed therapies. 50,000 migraineurs (sample derived from the Consumer Research Bureau) in the UK were invited to self-complete a questionnaire (during Q2-Q3, 1998). 9770 questionnaires were included in the analysis. With the advent of improved diagnosis and medications, the present study was undertaken to assess the impact and severity of migraine on the normal activities, attitudes and relationships of known migraineurs. The efficacy and control achieved by a range of therapeutic interventions were also considered. In order to identify the headache characteristics of this self-selected migraine patient population, diagnosis was confirmed by information relating to quality of headache (frequency, duration and symptomatology); the extent of restrictions on specific daily activities was also used to provide severity characteristics. A majority believed that they could not control their migraine and a significant proportion believed that migraine controlled their day-to-day life. Despite this, sufferers may not consult general practitioners (GPs) owing to previous experience, expectations of inadequate therapeutic intervention and/or perceived lack of physician empathy. This study is both opinion-based and awareness-based, and confirms known statistics while also providing further clarification on the overall effect of migraine on associated emotional and physical relationships, and on migraineurs' use and opinion of a range of available medications.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10640257     DOI: 10.1185/03007999909116495

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  13 in total

1.  A qualitative study of migraine involving patient researchers.

Authors:  Judith Belam; Gill Harris; David Kernick; Frances Kline; Krissy Lindley; Jayne McWatt; Annie Mitchell; Debbie Reinhold
Journal:  Br J Gen Pract       Date:  2005-02       Impact factor: 5.386

2.  Online Data Collection in Women's Health Research: A Study of Perimenopausal Women with Migraines.

Authors:  Margaret F Moloney; Ora L Strickland; Alexa Dietrich; Stuart Myerburg
Journal:  NWSA J       Date:  2004-10-01

Review 3.  Migraine and functional impairment.

Authors:  Jan Lewis Brandes
Journal:  CNS Drugs       Date:  2009-12       Impact factor: 5.749

4.  The burden of migraine in Spain: beyond direct costs.

Authors:  Xavier Badia; Sol Magaz; Laura Gutiérrez; Jordi Galván
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

5.  Children and adolescents with headache: what do they need?

Authors:  David Kernick; Deborah Reinhold
Journal:  J Headache Pain       Date:  2008-06-10       Impact factor: 7.277

6.  A case of chronic migraine remission after chiropractic care.

Authors:  Peter J Tuchin
Journal:  J Chiropr Med       Date:  2008-06

7.  GPs' classification of headache: is primary headache underdiagnosed?

Authors:  David Kernick; Sally Stapley; William Hamilton
Journal:  Br J Gen Pract       Date:  2008-02       Impact factor: 5.386

Review 8.  WITHDRAWN: Eletriptan for acute migraine.

Authors:  L A Smith; A D Oldman; H J McQuay; R A Moore
Journal:  Cochrane Database Syst Rev       Date:  2007-07-18

Review 9.  Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life.

Authors:  Dawn C Buse; Marcia F T Rupnow; Richard B Lipton
Journal:  Mayo Clin Proc       Date:  2009-05       Impact factor: 7.616

10.  Global trends in migraine care: results from the MAZE survey.

Authors:  Jan Lewis Brandes
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.